Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 10/20 | 0.61 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.61 |
| ▸ | AKR1A1 | P14550 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197081 | 0.91 | AKR1B1 (0.75) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL10575841 | 0.83 | AKR1B1 (0.54) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL1823243 | 0.78 | AKR1B1 (0.47) | AKR1B1AKR1B10AKR1A1 | |
| SCHEMBL9669362 | 0.77 | AKR1B1 (0.76) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL9668837 | 0.77 | AKR1B1 (0.76) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL2855039 | 0.76 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL9250816 | 0.76 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1MAPT | |
| (R,S)-Fidarestat SCHEMBL48828 | 0.76 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT | |
| SCHEMBL8311471 | 0.76 | AKR1B1 (0.83) | AKR1B1AKR1B10AKR1A1MAPT | |
| Fidarestat SCHEMBL48827 | 0.76 | AKR1B1 (1.00) | AKR1B1AKR1B10AKR1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536212-B2 | Protective agent for retinal nerve or optic nerve | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2013-09-17 | — | — | US | disclosed |
| US-8097640-B2 | Prophylactic or therapeutic agent for diabetic maculopathy | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-7910615-B2 | Prophylactic or therapeutic agent for diabetic maculopathy | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20100305177-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETIC MACULOPATHY | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100216856-A1 | PROTECTIVE AGENT FOR RETINAL NERVE OR OPTIC NERVE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20080319038-A1 | PREVENTATIVE OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20070299119-A1 | Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2007-12-27 | — | — | US | disclosed |
| US-20070293556-A1 | Prophylactic or Therapeutic Agent for Diabetic Maculopathy | SANWA KAGAKUYUSHO CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305177-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETIC MACULOPATHY | TXNRD2, TXNRD1, GPR119 | AKR1B1 651/4885AKR1B10 1139/4885AKR1A1 378/4885 |
| US-20070299119-A1 | Prophylactic or Therapeutic Agent for Severe Diabetic Retinopathy | TXNRD3, GPR119, ALDH1A2 | AKR1B1 669/4885AKR1B10 1134/4885AKR1A1 592/4885 |
| US-20070293556-A1 | Prophylactic or Therapeutic Agent for Diabetic Maculopathy | TXNRD2, GPR119, TXNRD1 | AKR1B1 842/4885AKR1B10 1424/4885AKR1A1 518/4885 |
| US-20080319038-A1 | PREVENTATIVE OR THERAPEUTIC AGENT FOR ACUTE RENAL FAILURE | ATP6V1B1, GLS, REN | AKR1B1 1716/4885AKR1B10 2364/4885AKR1A1 1940/4885 |
| US-20100216856-A1 | PROTECTIVE AGENT FOR RETINAL NERVE OR OPTIC NERVE | ALDH1A2, AKR1C3, ALDOA | AKR1B1 8/4885AKR1B10 14/4885AKR1A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.